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REVIEW

Stem cells for the treatment of neurodegenerative
diseases
Elise Dantuma, Stephanie Merchant and Kiminobu Sugaya*

Abstract
Stem cells offer an enormous pool of resources for the
understanding of the human body. One proposed use
of stem cells has been as an autologous therapy. The
use of stem cells for neurodegenerative diseases has
become of interest. Clinical applications of stem cells
for Alzheimer disease, Parkinson disease, amyotrophic
lateral sclerosis, and multiple sclerosis will increase in
the coming years, and although great care will need
to be taken when moving forward with prospective
treatments, the application of stem cells is highly
promising.

Introduction
Since their discovery, stem cells have altered the perception of the human body and revolutionized medical
research. The understanding of how the human body
develops and repairs itself has improved [1]. Because of
this, we are able to expand upon the possibilities of stem
cell use within the human body. As a result, interest in
stem cells as therapies has increased [1].
Research into the use of stem cells for the treatment of
neurodegenerative diseases, such as Alzheimer disease
(AD), Parkinson disease (PD), amyotrophic lateral
sclerosis (ALS), and multiple sclerosis (MS), has become
a growing interest in the medical community. Each of
these diseases aﬀects diﬀerent areas and structures of the
central nervous system (CNS). An extensive initiative to
investigate stem cells as possible treatments for these
four diseases has occurred. Stem cells hold a great opportunity for each of these diseases as a form of replacement
or protective therapy. Although this is not meant to be an
all-inclusive review of current stem cell research within
neurodegenerative disease, we review the major
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opportunities and obstacles stem cells hold for the future
of treatments for AD, PD, ALS, and MS.

Stem cells and their opportunities and limitations
Stem cells were discovered in the early 1960s [2,3], and
knowledge about their characteristics and composition
has come a long way. Stem cells are generally deﬁned as
cells that are capable of self-renewal and that possess the
ability to diﬀerentiate into multiple types of cells. On the
basis of their diﬀerentiation abilities, stem cells can be
classiﬁed as totipotnet, pluripotent, or multipotent. Totipotent stem cells are capable of diﬀerentiating into any
type of cell within the body, including extra-embryonic
tissue, and can be isolated from only the four-cell stage of
the embryo. Isolated from the blastocyst of the embryon,
pluripotent stem cells are capable of diﬀerentiation into
any cell within the body, and so they are able to give rise
to cells from any of the three major tissue lineages:
ectoderm, mesoderm, and endoderm. Multipotent stem
cells are capable of diﬀerentiation into only the select
types of cells from which they are derived and can be
isolated from various sources within the adult human
body. As the human body develops, the margin of
diﬀerentiation capability begins to be reduced from a
totipotent state to a pluripotent state and lastly to a
multipotent capability.
Naturally occurring stem cells generally include
embryonic stem cells (ESCs), fetal stem cells (FSCs), and
adult stem cells. Obtained from the blastocyst, ESCs are
pluripotent and proliferate quite well in culture. Given
these two qualities, ESCs appear to oﬀer both a signiﬁcant number of cells and the ability to germinate into a
variety of diﬀerent cell types [4]. ESCs have the most
ability to be used in a clinical setting since they are able to
give rise to multiple types of cells; however, there are
multiple ethical concerns with their use [5,6] and the risk
of adverse reactions, such as an immune reaction or
tumor formation or both [7].
As a source of multipotent stem cells, fetal organs
contain FSCs. The several advantageous qualities of FSCs
include their adaptability to their environment, migration
capabilities, lack of teratoma formation, and rejections in
vivo [8].
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Adult stem cells are classically deﬁned as multipotent
cells, which are deﬁned by their tissue of origin. Multiple
areas within the adult body, including bone marrow,
muscle, brain, and liver, contain an endogenous adult
stem cell population [1]. The key beneﬁt of adult stem
cells is their potential use in autologous therapies, in
which cells can be harvested and used within the same
patient. This beneﬁt eliminates the ethical concerns and
risks that ESCs bear. As advantageous as adult stem cells
appear to be, the limited diﬀerentiation ability restricts
universal use within the body.
Because naturally occurring stem cells have limitations,
scientists have developed a method for increasing
pluripotency within non-pluripotent cells. The latter cells
are termed induced pluripotent stem (iPS) cells, and
multiple studies cite the reprogramming process that
uses speciﬁc transcription factors, such as Oct4, Sox2,
Klf4, and c-Myc, to induce pluripotency [9-12]. Some
argue that the use of only two of these factors is suﬃcient
for iPS cell formation [13,14]. iPS cells open up the
possibility of using a patient’s own somatic cells, through
reprogramming, for treatment. However, iPS cells have
limitations as well. First, the process of creating these
types of cells is low in eﬃciency [15]. The fact that a large
number of starting cells are needed for the reprogramming process makes this a challenging beginning.
Second, the use of viruses for transduction of the
pluripotency factors within iPS cells poses a problem of
possible integration into the host genome if these factors
become reactivated [16]. Lastly, iPS cells have the ability
the produce teratomas, although the risk is less signiﬁcant compared with ESCs [16]. Researchers have attempted to address these disadvantages. The low eﬃciency of
reprogramming iPS cells may be related to the p53mediated DNA damage [17], and so inhibiting p53 may
increase the conversion of the cells but may increase the
risk of tumorigenesis from iPS cells as well. The second
issue has been attacked in two ways. One is to use nonviral transfection [18], although the eﬃcacy still needs to
be worked out and long-term control of the gene
expression may be diﬃcult. Another approach would be
the use of Cre-recombinase excisable viruses [19] or
delivery of recombinant protein [20]. However, we still
must prove the functionality and safety of the resulting
cells, and stem cell-based therapy may still have hurdles
to overcome but its future is very promising.

Stem cells and neurodegenerative diseases
Neurodegenerative diseases hold an opportunity for the
clinical use of stem cells. In neuroscience, the discovery
of neural stem cells (NSCs) and subsequent research [21]
have nulliﬁed the previous idea that the adult CNS was
not capable of neurogenesis [22,23]. Indeed, neurogenesis
occurs throughout life. NSCs are believed to reside
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within the subventricular zone of the lateral ventricle
wall and the subgranular zone of the hippocampal
dentate gyrus, where neurogenesis occurs [22,24]. NSCs
give rise to glial-restricted precursors (GRPs) and neuronrestricted precursors, both of which diﬀerentiate into
astrocytes, oligodendrocytes, or neurons [23]. Another
study demonstrated that transplanted NSCs isolated
from a 9-week-old human fetus have the ability to
diﬀerentiate into neural cells and improve cognition in
aged rats [25]. Hence, the idea of using NSCs for
neurodegeneration treatment is intriguing.
However, NSCs are not so easy to access as a source of
stem cells for possible use to treat neurodegenerative
diseases. Previously, many studies have suggested the use
of bone marrow-derived mesenchymal stem cells (MSCs)
for regeneration of neural cells since MSCs are present in
bone marrow and are relatively easily accessible within
the human body. However, the consensus now is that
naive MSCs do not become neural cells. Our previous
study suggests that MSCs can be dediﬀerentiated into
cells similar to iPS cells by increasing the expression of a
single ESC gene, nanog. We were able to transdiﬀerentiate
MSCs into neural cell lineage after dediﬀerentiation. This
result indicates that we may be able to use adult stem
cells as an autologous source to create iPS cells. This
technology and iPS cells together may oﬀer the potential
for autologous neuroregenerative therapies to be
developed along with the ease of access to a patient’s own
cells. Another key factor for the development of stem cell
treatments for neurological diseases will be the understanding of the pathology of the speciﬁc disease. Each
disease will need to be assessed individually and each
treatment will need to be tailored accordingly.

Alzheimer disease
As one of the most common causes of dementia, AD
aﬀects 5.3 million Americans [26]. AD, known for its
quintessential hallmarks of amyloid-β peptide (Aβ)
plaques and neuroﬁbrilary tangles [21,27-29], results in
the death of several types of neuronal lineage cells within
multiple regions of the brain [29-31], speciﬁcally
cholinergic neurons [23]. Discovered in 1987, the human
amyloid precursor protein (APP) gene is located on
chromosome 21 and codes for a type I transmembrane
protein [32]. Aβ plaques are generated by γ- and βsecretases that cleave APP at speciﬁc amino acids [33],
and neuroﬁbrilary tangles are composed of tau proteins
that are hyper-phosphorylated, resulting in neuron impairment [34]. Both of these hallmarks lead to cognitive
impairment and loss of memory [29]. However, the direct
pathogenesis of AD still eludes researchers [35].
Currently available drugs for the treatment of AD are
purely for symptoms [36] and among these drugs are the
cholinesterase inhibitors [33,37]. After acetylcholine is
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released from the synapse, cholinesterase inhibitors delay
its degradation, leading to improved cognition [33].
However, these types of drugs have only a modest eﬀect,
which can be variable among patients [38]. Another type
of drug available for AD patients is an N-methyl-daspartate (NMDA) receptor antagonist named memantine [33]. Memantine prevents the NMDA receptors
from overstimulation that can lead to toxicity [33]. Since
the current treatments have only marginal eﬀects and
greatly vary in their eﬀectiveness in patients, the need for
new treatments is great. It is estimated that there will be
615,000 new cases by 2029 and 959,000 by 2050 [26].
Owing to this increase in the number of new cases, a
great burden will be placed on health-care systems [26].
The need for a proper treatment or cure for AD is
imperative.
Recently, Blurton-Jones and colleagues [29] published a
study in which they injected NSCs into the hippocampal
regions of the brain of both a transgenic AD mouse
model and an age-matched non-transgenic mouse model.
Interestingly, the mice improved in cognitive function
and there was no change to the existing Aβ plaques or
neuroﬁbrilary tangles [29]. Instead, the authors discovered brain-derived neurotrophic factor, which is
important for neuron outgrowth, and synapse formation
increased [39], leading to improved cognition through
increased synaptic density [29]. This demonstrated cognition could be improved without the need for modifying
the existing pathological conditions [29].
Although the physiological function of APP is not clear,
recent reports indicate that it may play an important role
in regulating stem cell biology or adult neurogenesis [40].
We found that APP increased chemokine levels to alter
cell migration [41]. We also showed that increased APP
caused glial diﬀerentiation of human NSCs in vitro and in
vivo. This may create the problem of how to regenerate
neurons by augmentation of NSCs when APP levels are
high. Also, increased levels of APP, found in Down
syndrome patients, who develop AD in later life, may
exhaust endogenous NSC populations because of
increased premature glial diﬀerentiation of the cells [42].
This APP function may need to be considered for
neuroregenerative therapies under a pathogenic APP
environment within the AD brain. Increased levels of
APP in the brain not only reduce NSCs, which may
increase the risk of AD, but also increase the level of glial
diﬀerentiation of stem cells upon transplantation, reducing the eﬃcacy of therapy to improve cognitive function
[42,43]. Thus, the levels of APP may need to be reduced
before transplantation of stem cells, and our previous
study showed signiﬁcant neurogenesis from NSC transplantation in APP transgenic mice but only after APP
level was reduced by phenserine treatment [34]. NSCs
may also be useful to augment growth factors. A
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transgenic model of AD showed improvement in cognition by release of BDNF (brain-derived neurotrophic
factor) after NSCs [29]. NSCs are also reported to express
neurotrophic factors and promote axonal growth in
spinal cord injury [44].
Many experimental studies show a beneﬁcial neuroprotective eﬀect of hemopoietic growth factors such as
granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), stem cell factor, vascular endothelial growth factor (VEGF), and stromal cell-derived
factor-1-alpha (SDF-1-alpha) in ischemic stroke [45,46].
Bone marrow-derived MSCs are reported to protect or
reduce ischemic damage by releasing insulin-like growth
factor-1 (IGF-1) in transient ischemic model animals.
Furthermore, NSCs modiﬁed by transfection of vascular
endothelial growth factor provided neuroprotection after
transient focal cerebral ischemia [47]. Despite promising
results from animal models, the lack of data in humans
hampers eﬃcacy assessments of growth factors on
neurodegenerative disease therapy. In clinical study with
stroke patients, MSC-treated patients showed signiﬁcant
and consistent improvement in the Barthel index and
modiﬁed Rankin score over the control patients during
the follow-up period up to 12 months [48]. More recently,
a long-term follow-up study of intravenous autologous
MSC transplantation in patients with ischemic stroke
showed very promising results [49]. These results may
support the use of stem cells to augment growth factor in
AD in the future.

Parkinson disease
First described in 1817, PD, the second most common
neurodegenerative disease [50], is a neurological degenerative disease that results in the loss of dopaminergic
neurons within the substantia nigra [51,52], leading to a
loss of motor function. Lewy body formation and neuritis
are the pathological hallmarks of this disease, and the
speciﬁc etiology is still unknown [52]. PD itself is not
fatal but complications from the disease can lead to
death.
Current treatments for PD include drug regimens and
surgery. However, these treatments are purely palliative.
The current drug treatment for PD supplies the surviving
dopamine neurons with l-Dopa, which they convert to
dopamine [53]. Eventually, however, all of the remaining
dopamine neurons die and treatment with l-Dopa is
ineﬀective [53].
MSCs have been proposed as a potential treatment for
PD. Park and colleagues [54] investigated the use of
MSCs in a PD mouse model to observe a potential neuroprotective eﬀect on neuronal loss. MSCs signiﬁcantly
preserved the number of dopaminergic neurons and
tyrosine hydroxlase-positive cells in vitro and in vivo [54].
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In a diﬀerent study, Murrell and colleagues [55] proposed
the use of adult olfactory stem cells for recovery of
dopaminergic neurons in PD. The adult olfactory stem
cells were diﬀerentiated into NPCs and were capable of
becoming dopaminergic-like neurons both in vitro and in
vivo [55]. NSCs have also been investigated for their use
as possible treatments for PD. Yasuhara and colleagues
[56] tested the use of NSCs on the behavioral beneﬁts
and protective eﬀects in PD in vivo. When NSCs were
immediately transplanted after 6-hydroxydopamine lesion
formation in mice, tyrosine hydroxlase neurons were
protected and PD symptoms were reduced [56].
The study of Kim and colleagues [57] supports the use
of ESCs for cell replacement therapy as the authors have
shown that highly enriched populations of midbrain
NSCs can be derived from mouse ESCs. The dopamine
neurons generated by these stem cells show electrophysiological and behavioral properties expected of
neurons from the midbrain [57]. To move forward with
these studies, further experiments must be developed to
show methods of enriching the cell of interest and
demonstrate that these cells show functions that will
assist in treating the disease.
Other studies have investigated the use of iPS cells,
derived from mouse ﬁbroblasts, to produce neural
progenitor cells, which are multipotent adult stem cells,
for injection into 6-hydroxydopamine-lesioned rats [58].
The injected derived iPS cells were capable of migration
to various areas of the brain, diﬀerentiated into glia and
neurons, and integrated into the host brain [58].
Additionally, the eﬃciency of their experiment was high,
and almost all of the animals showed high numbers of
tyrosine hydroxlase-positive cells [58]. The study of
Iacovitti and colleagues [59] supports this by deriving
midbrain dopaminergic (mDA) neurons from a commercially available human induced pluripotent stem (hiPS)
cell line, IMR90 clone 4. The authors were able to
produce cells that followed the same lineage pathway as
H9 human ESCs and that showed the same expression
levels of dopamine and DOPAC (dihydroxyphenylacetic
acid) [59]. The mDA hiPS cells that were transplanted
into 6-OHDA-leisioned PD rats not only survived in the
long term but also integrated into the host brain, but it
was also noted that many Nestin+ tumor-like cells
remained at the site of graft [59]. The future success of
cell replacement therapies for PD will depend on the
ability to select the appropriate mDA cell lineage.

Amyotrophic lateral sclerosis
ALS, also known as Lou Gehrig’s disease, is a neurodegenerative disease aﬀecting the spinal cord and brain
stem and typically is adult-onset. Speciﬁcally, the upper
and lower motor neurons die, leading to progressive
paralysis [60]. Over 150 years ago, the classic hallmarks
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of this disease, including the death of motor neurons and
progressive atrophy, were described [50]. Generally, the
mean onset age is 55 years, and prognosis after diagnosis
is only 2 to 5 years [50]. The cause of ALS is still
unknown.
In 2006, Chi and colleagues [61] performed a study that
observed the role of neural progenitor cells in an ALS
disease mouse model. Interestingly, the degeneration of
the motor neurons stimulated neurogenesis and neural
progenitor cell proliferation [61]. In another study, Corti
and colleagues [62] transplanted NSCs positive for both
Lewis X and a chemokine receptor into the spinal cord.
Disease progression was delayed and survival time
increased for transplanted mice because of an integration
of the transplanted cells into the spinal cord [62]. These
studies may indicate that neurotropic factors produced
by transplanted stem cells protect neurons from the
environment of ALS and increase neurogenesis. Since
abnormality of astrocytes is one of the hallmarks of ALS,
replacement of glia cells by adult glial progenitors [63]
and GRPs [64] has been proposed. Studies by Maragakis
and colleagues [63] and Rothstein and colleagues [64]
show that astrocyte dysfunction occurs in human ALS
and SOD1G93A animal models. The authors showed
success in transplantation of lineage-restricted astrocyte
precursors, GRPs. GRPs not only survived in the diseased
environment but also diﬀerentiated into astrocytes and
reduced microgliosis in SOD1G93A rat cervical spinal cord
[64]. These ﬁndings demonstrate the potential ability for
transplantation-based astrocyte replacement and show
that cell transplantation to the cervical spinal cord is a
promising therapeutic strategy for slowing focal motor
neuron loss associated with ALS [64]. These preclinical
animal studies are promising and may develop into
clinical applications in the near future. On the other
hand, replacement of degenerating motor neurons may
create some controversy because of the lack of knowledge
of whether the patients’ cells produce healthy motor
neurons and the ability of these cells to survive under the
pathological condition. A recent study gives us an
optimistic view of the development of neuroregeneration
therapy of ALS. Dimos and colleagues [65] successfully
produced motor neurons from iPS cells derived from an
82-year-old patient with familial ALS.
In 2008, Mazzini and colleagues [66] published a
clinical-based experiment in which MSCs were autologously transplanted to ALS patients through a spinal cord
injection. The authors state that the results of this study
show that MSCs are safe for clinical use for treatment of
ALS and showed a slowing in the decline in the forced
vital capacity and functional rating scores of some
patients [66]. However, as the study notes, this experiment was performed on a small number of patients and
will need to be replicated with a large number of patients
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in order to verify the results [66]. Mazzini’s group [67]
did replicate this experiment with a larger number of
patients, publishing the results in 2010. Although similar
results were obtained, the study lacked signiﬁcant
changes in the progression of the disease, which were
obtained in the previous study [67].

Multiple sclerosis
One of the major qualities of MS, a CNS autoimmune
disease, is the initial relapse-remitting cycle of the
disease, eventually leading to progression of the disease
without relapses [68]. The myelin sheath, the primary
target, is degraded and this degradation aﬀects neurons
[50]. Unlike AD, PD, and ALS, MS predominately aﬀects
young adults and has a higher rate of occurrence in
females [50]. MS is also a heterogeneous disease, and so
the degree of the disease can range from fairly benign to
extremely debilitating and the stages of disease can range
from only relapses to progressive [68]. Again, currently
available treatments are purely symptomatic.
Current approaches for MS treatment include monoclonal antibodies, chimeric molecules, and hematopoietic
stem cells (HSCs) [69]. The general aim of HSCs for MS
treatment is to completely correct the immune system
anomaly within the patient [69]. A study by Aharonowiz
and colleagues [70] investigated the use of human ESCderived neural precursor cells into the cerebral ventricles
of an MS mouse model. The transplanted human ESCderived neural precursor cells reduced the clinical signs
of MS and had a neuroprotective eﬀect by immunosuppression within the mice [70].
The use of myelin-forming cell transplantation to
restore myelin at sites of myelin loss has been
experimented with since the 1970s [71]. However, the
myelin-forming cells, especially those cells that are
linage-restricted, are very limited in their growth and
ability to regenerate myelin [71]. Therefore, stem cells
might hold the answer for cell transplant treatments in
MS [71]. In 2009, Burt and colleagues [72] published a
study in which non-myeloablative HSCs were autologously transplanted to relapse-remitting MS patients.
Neurological improvement and a slowing in progression
were observed after transplantation [72].
Conclusions
Clinical application of stem cells, whether ESCs, FSCs,
adult stem cells, or iPS cells, is increasingly becoming a
reality. However, great care will need to be taken when
moving forward. The pathological environments of
neurodegenerative diseases will need to be assessed to
observe their eﬀect on transplanted stem cells. Additionally, the migratory patterns of transplanted stem cells will
need to be observed and possibly controlled. With
movement toward clinical use of stem cells, protocols
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will have to undergo extensive scrutiny of their preclinical
safety and beneﬁt analyses, projected experiments, and
informed consent protocols [73].
In 2008, the International Society for Stem Cell
Research released a set of recommended guidelines for
the development of stem cell-based treatments [74].
These recommendations include the use of experts in
stem cell biology for peer review of research ranging
from preclinical to clinical, emphasizing risks involved
with stem cell-based therapies within the voluntary
informed consent, new oversight criteria for medical
innovative care that falls outside of the realm of a clinical
trial, and the equality of beneﬁts of stem cell treatments
[74].
In regard to the number of clinical trials, the number of
AD and PD versus ALS and MS clinical trials is highly
skewed. The reason for this perhaps is that, once their
condition is diagnosed, ALS and MS patients have a
limited prognosis. AD and PD patients have a longer
prognosis. Potentially, the US Food and Drug Administration is more inclined to initiate clinical trials for ALS
and MS because of the risk-to-beneﬁt relationship.
However, an increase in clinical trails for AD and PD is
inevitable because of the high cost of ‘human life’ these
two diseases present, along with the ﬁnancial burden of
cost of care.
Although the issues presented above do need to be
resolved before the clinical application of stem cells can
be realized, the advancement of these technologies is
building. The number of stem cell clinical trials will
increase tremendously and conceivably some will become
standard treatments.
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